Purple Biotech Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
-0.31 (-5.88 %)
(As of 08/4/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume252,230 shs
Average Volume1.18 million shs
Market Capitalization$78.00 million
P/E RatioN/A
Dividend YieldN/A

Receive KTOV News and Ratings via Email

Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter.

Purple Biotech logo

About Purple Biotech

Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.78 out of 5 stars

Medical Sector

769th out of 1,311 stocks

Pharmaceutical Preparations Industry

381st out of 647 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Purple Biotech (NASDAQ:KTOV) Frequently Asked Questions

Is Purple Biotech a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Purple Biotech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Purple Biotech stock.
View analyst ratings for Purple Biotech
or view top-rated stocks.

What stocks does MarketBeat like better than Purple Biotech?

Wall Street analysts have given Purple Biotech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Purple Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When did Purple Biotech's stock split? How did Purple Biotech's stock split work?

Purple Biotech shares reverse split on Saturday, August 22nd 2020. The 1-10 reverse split was announced on Friday, August 21st 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 21st 2020. An investor that had 100 shares of Purple Biotech stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for KTOV?

1 analysts have issued 12 month price objectives for Purple Biotech's stock. Their forecasts range from $25.00 to $25.00. On average, they expect Purple Biotech's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 404.0% from the stock's current price.
View analysts' price targets for Purple Biotech
or view top-rated stocks among Wall Street analysts.

Who are Purple Biotech's key executives?

Purple Biotech's management team includes the following people:
  • Mr. Isaac Israel, CEO & Director (Age 42, Pay $564.48k)
  • Mr. Gil Efron CPA, Deputy CEO & CFO (Age 54, Pay $356.91k)
  • Mr. Avraham Shlomo Ben-Tzvi, Group Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 49)
  • Mr. Simcha Rock CPA, M.B.A., CPA, MBA, Strategic Advisor & Director (Age 70)
  • Dr. Bertrand C. Liang, Chief Medical Officer (Age 57)
  • Dr. Michael Schickler, Head of Clinical Operations (Age 62)

Who are some of Purple Biotech's key competitors?

What other stocks do shareholders of Purple Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Purple Biotech investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), Southwestern Energy (SWN), VBI Vaccines (VBIV), Onconova Therapeutics (ONTX), Advanced Micro Devices (AMD), Vaxart (VXRT), Amarin (AMRN) and Citius Pharmaceuticals (CTXR).

When did Purple Biotech IPO?

(KTOV) raised $13 million in an IPO on Friday, November 20th 2015. The company issued 3,200,000 shares at $4.13 per share. Rodman & Renshaw (a unit of H.C. Wainwright & Co.,) and Joseph Gunnar acted as the underwriters for the IPO.

What is Purple Biotech's stock symbol?

Purple Biotech trades on the NASDAQ under the ticker symbol "KTOV."

What is Purple Biotech's stock price today?

One share of KTOV stock can currently be purchased for approximately $4.96.

How much money does Purple Biotech make?

Purple Biotech has a market capitalization of $78.00 million and generates $1 million in revenue each year. The company earns $-5,850,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

How many employees does Purple Biotech have?

Purple Biotech employs 9 workers across the globe.

What is Purple Biotech's official website?

The official website for Purple Biotech is

Where are Purple Biotech's headquarters?

Purple Biotech is headquartered at ONE AZRIELI CENTER ROUND TOWER 132 MENACHEM BEGIN ROAD, TEL AVIV L3, 6701101.

How can I contact Purple Biotech?

Purple Biotech's mailing address is ONE AZRIELI CENTER ROUND TOWER 132 MENACHEM BEGIN ROAD, TEL AVIV L3, 6701101. The company can be reached via phone at 972-3933-3121 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.